Mesa Laboratories Inc
NASDAQ:MLAB
Mesa Laboratories Inc
NASDAQ:MLAB
Price:
120.61 USD
1.69%
Updated:
May 17, 2024
P/S
Price to Sales
Price to Sales
3.1
Current
4.3
Median
2.4
Industry
Lower
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=3.1
Market Cap
/
650.6m
Revenue
212.9m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Mesa Laboratories Inc
NASDAQ:MLAB
|
650.6m USD | 3.1 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
181B USD | 4.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
140.6B USD | 19.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.8B USD | 6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.2B USD | 3.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
109.1B USD | 7.4 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
68B USD | 3.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
59.4B EUR | 2.7 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
53.6B USD | 8.7 | |
| US |
|
Dexcom Inc
NASDAQ:DXCM
|
52.1B USD | 13.7 | |
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
373.7B CNY | 10.4 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
3
2-Years Forward
P/S
2.7
3-Years Forward
P/S
2.5
You don't have any saved screeners yet
